Merck Serono, the pharmaceutical division of Merck KGaA, of Darmstadt, Germany, signed a deal with Philochem AG, of Zurich, Switzerland, in which Philochem will supply specific monoclonal antibodies to Merck Serono, to be used in the search for molecular biomarkers of oocyte and embryo quality for a test to be used by physicians. Terms of the agreement were not disclosed.